Belimumab (TNFSF13B/CD257) 抗体,

Belimumab (TNFSF13B/CD257) 抗体, 单克隆，Belimumab (TNFSF13B/CD257) Antibody, Monoclonal，Belimumab (TNFSF13B/CD257) 抗体, 单克隆,Belimumab (TNFSF13B/CD257) Antibody, Monoclonal

产品名称：Belimumab (TNFSF13B/CD257) 抗体, 单克隆-Belimumab (TNFSF13B/CD257) Antibody, Monoclonal

产品货号：PSI-10-282-0.1mg

产品规格：0.1mg

背景资料：Belimumab is an intravenous immunosupressant for the adjunctive treatment of systemic lupus erythematosus (SLE). More specifically, it is a fully human recombinant IgG1λ monoclonal antibody produced from a recombinant NS0 cell line stably transfected with the belimumab heavy chain and light chain genes. It is the first biological treatment approved for the indication of SLE. Concomitant use with live or inactivated vaccines must be avoided. Belimumab was FDA approved on March 9, 2011. Belimumab consists of 2 heavy chains, and 2 light chains of the lambda subclass. Each heavy chain contains 452 amino acid residues and each light chain contains 214 amino acid residues. There are 3 post-translational modifications: a conserved N-linked glycosylation on the CH2 domain at Asn 303 of the heavy chain, the conversion of the N-terminal glutamine residue of the heavy chain into pyroglutamate, and loss of C-terminal lysine residue of the heavy chain.

保存建议：Belimumab (TNFSF13B/CD257) 抗体, 单克隆-Belimumab (TNFSF13B/CD257) Antibody, MonoclonalStore at -80℃

应用类型：

点击：Belimumab (TNFSF13B/CD257) 抗体, 单克隆-Belimumab (TNFSF13B/CD257) Antibody, Monoclonal查看更详细产品说明，更多应用、储存、价格、货期等信息请垂询艾美捷科技有限公司。更多ProSci公司特色试剂盒、特色抗体以及特色试剂等产品评论，请点击查看艾美捷特色产品中心。